Losing is a state of mind.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BMSN news out on clinical trials !
NEWS BMSN
Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate(TM) Bone Marrow Failure Product
Bio-Matrix Subsidiary's Publication Is Scientific Basis for IND Submission Currently in Preparation
SAN DIEGO, CA, Jan 24, 2013 (MARKETWIRE via COMTEX) -- Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate(TM) bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf. The publication is an overview of the Investigational New Drug (IND) application that the company plans to file for initiating clinical trials.
HemaXellerate(TM) is a cell therapy product developed by Regen BioPharma that uses fat derived from the patient as a source of "healing cells" to stimulate bone marrow production of blood cells. These "healing cells" are termed "endothelial cells" and are a critical component of the blood production machinery of the bone marrow that is damaged in patients with bone marrow failure.
Intellectual property covering the HemaXellerate(TM) product include US Provisional Patent applications 61/648898 - Acceleration of Hematopoietic Reconstitution by Placental Endothelial and Endothelial Progenitor Cells and 61/670791 - Treatment of Hematopoietic Disorders filed by Regen, as well as an option to exclusively license issued US Patent #6,821,513.
Currently, the only way to stimulate production of blood from bone marrow is through administration of growth factors. The overall market for growth factors is $18 billion per year. Unfortunately, growth factors require repeated administration, are expensive, and in many patients are ineffective.
"Treatments available today for patients with insufficient bone marrow function are a 'band-aid' solution that require repeated administration and do not address the underlying cause of bone marrow failure," said David Koos, Chairman and CEO of Bio-Matrix, and a co-author of the publication. "We believe that HemaXellerate(TM) offers the possibility to actually heal damage that has occurred to the bone marrow and thus more naturally treat the core of cause of bone marrow inactivity."
The publication contained data obtained from independent laboratories supporting the use of HemaXellerate(TM) as an alternative to growth factor therapy and was a co-authored by stem cell pioneers Dr. Amit Patel from University of Utah, and Dr. Michael Murphy from Indiana University. Additionally, the paper was co-authored by companies working in the field of stem cells including Cook Biotechnology and Medistem, Inc.
Regen BioPharma's first indication of HemaXellerate(TM) will be patients with aplastic anemia who are drug resistant and not eligible for bone marrow transplantation. Demonstration of efficacy in this patient population is anticipated to lead the way for entry into the $18 billion hematopoietic growth factor market which includes conditions such as anemia, thrombocytopenia, and chemotherapy associated leukopenia.
About Bio-Matrix Scientific Group Inc. and Regen BioPharma, Inc.:
Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN) is a biotechnology company developing regenerative medicine therapies. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine patents in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. To follow our development, visit us at www.regenbiopharma.com.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks
Contact:
Bio-Matrix Scientific Group, Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
www.bmsn.us
Email Contact
SOURCE: Bio-Matrix Scientific Group, Inc.
CONTACT: http://www.bmsn.us/
http://www2.marketwire.com/mw/emailprcntct?id=45EDB13FB9134393
Copyright 2013 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech:Trials
well see whos right .
News on BMSN
bio-matrix scientific group (BMSN) Key Developments
Bio-Matrix Scientific Group, Inc. announced delayed annual 10-K filing
Dec 31 12
On 12/31/2012, Bio-Matrix Scientific Group, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Bio-Matrix Scientific Group, Inc. Announces Auditor Changes
Dec 10 12
On December 4, 2012 the Board of Directors of Bio-Matrix Scientific Group, Inc. approved the dismissal of Anton & Chia, LLP as the company's independent registered public accounting firm. On December 4, 2012, the Board of Directors of the company, acting as the company's Audit Committee, approved the engagement of Seale and Beers, CPA as its independent auditor.
Bio-Matrix Scientific Group, Inc. Appoints Anton & Chia, LLP as Auditor in Place of John Kinross-Kennedy CPA
Oct 3 12
On September 27, 2012 the Board of Directors of Bio-Matrix Scientific Group Inc. approved of the dismissal of John Kinross-Kennedy CPA as the company's independent registered public accounting firm. On September 27, 2012, the Board of Directors of the company, acting as the company's Audit Committee, approved the engagement of Anton and Chia, LLP as its independent auditor. On same date, September 27, 2012, the accounting firm of Anton & Chia, LLP was engaged as the company's new independent registered public accounting firm.
i read it but it said nothing about a date
what makes you say that
when is the news comming ?
we are now bullish again. congrats bmsn
that volume in BMSN makes every other bar on my 5 min chart invisible LOL
need close at least at .0025 for tomorrow to have a chance of being green . dont want that daily candle looking so weak
thats 20 grand . . . .
BMSN just went positive and L2 is thin . expecting FDA , MERGER , MEDICAL TRIALS NEWS within the month
you have a new a profile from a few days ago . you have no credibility here so shut up
we have to get green today in BMSN
IF BMSN opens green tuesday . WE RUN
thats not much to go on. could be a whole year before anything happens but i guess ill hold
so why does everyone expect something soon ?
you told me they expect news this year . Do you think it will be soon like maybe this month or even this week ?
end of day sell offf. runnnnnnnnnnnnn
thanks for the info . it doesnt explain why everyone expects a PR tomorow or soon though . thoughts ?
how soon can it be expected ? and where are you getting the info ?
WHAT NEWS ARE WE EXPECTING ?
on what ?
What news are we waiting on ?
if we close green we will be ok . if not , we need news
Shares Outstanding 216,948,784 a/o Jun 30, 2012
hard to attract buying pressure when your red for the day though
low volume , no sellers . just sitting here waiting for buyers at the moment is what BMSN is doing . However we do have a gap to fill and we are negative for the day so moving up might be a little challenge
where do you see that ?
AMBS . more than one PR out today. LETS GO ALREADY. MOVE MOVE MOVE
AMBS NEWS
ambs making new highs. if it breaks .0096 say hello to another run
and hes gone . . . ambs , we run eod right now
kill that seller with 170 000 shares that keeps moving his order down and we will run
AMBS about to break again , and make new highs
AMBS broke resistance from previous run AND broke a daily double top
BROKE A DOUBLE TOP
DUSS chart please ?
Best short ever, going to wait for it to rebound then short it again . nice gains TWICE in a day. love SRGE
bad day to issue great news . wont see good volume and runs until next year . sucks we cudda had a great run